Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Hims & Hers health director buys $1.95m in stock

Published 23/05/2024, 06:22 am
HIMS
-

In a recent transaction, Christopher D. Payne, a director at Hims & Hers Health, Inc. (NYSE:HIMS), purchased shares of the company's stock, signaling confidence in the telehealth service provider. The transaction involved the acquisition of 110,000 shares at an average price of $17.7433, amounting to a total investment of approximately $1.95 million.

The shares were bought on May 21, 2024, with prices ranging from $17.64 to $17.855. The reported average price represents the weighted average of shares purchased at different prices within the specified range. Christopher D. Payne, through the Payne Family Trust dated September 17, 2020, now directly holds these shares.

Investors often monitor insider transactions such as these for insights into the sentiment of high-ranking executives and directors within the company. With this substantial purchase, Payne's actions may be interpreted as a positive sign about the company's future prospects.

Hims & Hers Health, Inc., headquartered in San Francisco, California, operates in the telehealth industry, providing a modern approach to health and wellness. The company's business model is focused on direct-to-consumer healthcare and wellness products, aiming to make healthcare more accessible and convenient.

The transaction was disclosed in a regulatory filing with the Securities and Exchange Commission, and the details, including the range of prices at which the stock was acquired, are available to the public. Shareholders and potential investors in Hims & Hers Health, Inc. can consider such insider transactions as one of many factors in their investment decisions.

InvestingPro Insights

Amidst the recent insider transaction by Christopher D. Payne, a director at Hims & Hers Health, Inc. (NYSE:HIMS), the company's financial metrics and market performance offer additional context for investors. The purchase of 110,000 shares by Payne reflects a notable vote of confidence, which is bolstered by the company's impressive returns and anticipated growth.

Hims & Hers Health has demonstrated a significant return over the last week, with a 26.88% price total return, and the momentum extends over the last month and three months, showcasing returns of 47.81% and 85.82%, respectively. These metrics indicate a strong market performance in the short term, which could be a contributing factor to Payne's investment decision.

From a financial standpoint, Hims & Hers Health has shown robust revenue growth in the last twelve months as of Q1 2024, with a 55.65% increase, signaling a rapid expansion of its telehealth services. This growth is further exemplified by the company's gross profit margin, standing at a healthy 82.41%. Despite operating at a loss, with an operating income margin of -0.54%, the company's liquid assets exceed short-term obligations, as per InvestingPro Tips, suggesting a stable financial position to support ongoing operations.

Investors looking for additional insights can find more InvestingPro Tips on Hims & Hers Health, Inc., including the expectation of net income growth this year and several analysts revising their earnings upwards for the upcoming period. With 14 additional tips available on InvestingPro, investors can gain a more comprehensive understanding of the company's potential. For those interested, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

Considering these financial metrics and market performance, the insider purchase by Christopher D. Payne may be seen as aligning with the company's promising trajectory. Hims & Hers Health, Inc. continues to navigate the competitive telehealth landscape with strategic growth and market resilience.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.